A Study of Zimberelimab(GLS-010) Combined With AVD for Newly Diagnosed Early-stage Hodgkin's Lymphoma

Launched by SUN YAT-SEN UNIVERSITY · Jun 12, 2023

Keywords

ClinConnect Summary

This clinical trial is examining how well a new treatment called Zimberelimab works when combined with a standard chemotherapy regimen (AVD) for patients with early-stage classical Hodgkin lymphoma. The study is being conducted at multiple locations and aims to find out if this combination is safe and effective, using advanced imaging techniques like PET/CT to guide treatment.

To participate in this trial, you need to be an adult aged 18 to 45 or over 60, with a confirmed diagnosis of early-stage classical Hodgkin lymphoma (Stages I-II) and at least one measurable tumor. Participants can expect regular check-ups and monitoring throughout the study to assess the treatment's effects and side effects. This trial is currently recruiting participants, and it offers a potential new option for those who may not be able to tolerate traditional chemotherapy. If you're considering this trial, it’s a great opportunity to help advance treatment for Hodgkin lymphoma while receiving close medical supervision.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Diagnosed with primary classical Hodgkin lymphoma (HL) based on histopathology.
• • 2. Stage I-II .
• • 3. At least one measurable target lesion（Lugano 2014）.
• • 4. Age 18 years or older (including 18 years) to 45 years (recent fertility requirements and concern about chemotherapy side effects), or age \>60 years (older patients who are frail and unwilling to undergo chemotherapy), male or female.
• • 5. ECOG PS 0-3,
• • 6. Expected survival ≥ 3 months.
• Exclusion Criteria:
• • 1. Hodgkin's lymphoma with nodular lymphocyte predominant type.
• • 2. Patients who are scheduled to undergo subsequent autologous stem cell transplantation.
• • 3. Contraindications to radiotherapy.
• • 4. With central nervous system (meningeal or parenchymal) involvement.
• • 5. Contraindications to immune checkpoint inhibitors.